Expression of cytokeratin 5/6 in epithelial neoplasms: An immunohistochemical study of 509 cases
Expression of cytokeratin 5/6 in epithelial neoplasms: An immunohistochemical study of 509 cases
复制标题
DOI：
10.1038/modpathol.3880483
复制
发表时间：
2002-01-01
期刊：
影响因子：
7.5
通讯作者：
Weiss, LM
中科院分区：
文献类型：
--
作者：
Chu, PGG;Weiss, LM
细胞角蛋白5/6（CK 5/6）免疫反应性在绝大多数恶性间皮瘤病例中可观察到，但在肺腺癌中很少见。因此，CK 5/6已被用于区分恶性间皮瘤和肺腺癌。然而，由于CK 5/6在非肺部肿瘤中的组织表达尚未明确界定，其在区分胸膜恶性间皮瘤与非肺腺癌的胸膜转移瘤，以及腹膜恶性间皮瘤与腹膜转移性腺癌方面的作用尚未得到充分探讨。我们通过免疫组织化学方法研究了509例各种上皮性肿瘤中CK 5/6的表达情况。我们发现，绝大多数鳞状细胞癌、基底细胞癌、胸腺瘤、唾液腺肿瘤和双相恶性间皮瘤病例CK 5/6呈阳性。此外，在24例移行细胞癌中的15例（62%）、10例子宫内膜腺癌中的5例（50%）、约三分之一的胰腺腺癌（38%）和乳腺腺癌（31%）以及四分之一的卵巢腺癌（25%）中检测到CK 5/6免疫反应性。我们的研究证实了CK 5/6免疫组织化学在区分双相间皮瘤和肺腺癌方面的诊断作用，但对其用于胸膜或腹膜恶性间皮瘤与胸膜或腹膜转移性非肺腺癌的鉴别诊断提出了警示，因为许多类型的非肺腺癌可能CK 5/6呈阳性。
Cytokeratin 5/6 (CK 5/6) immunoreactivity has been observed in the vast majority of cases of malignant mesothelioma but only rarely in pulmonary adenocarcinomas. Thus, CK 5/6 has been used to distinguish malignant mesothelioma from pulmonary adenocarcinoma. However, the utility of CK 5/6 in distinguishing pleural malignant mesothelioma from pleural metastases from nonpulmonary adenocarcinoma, as well as peritoneal malignant mesothelioma from peritoneal metastatic adenocarcinoma, has not yet been adequately addressed because the tissue expression of CK 5/6 in nonpulmonary neoplasms has not been well defined. We have studied the CK 5/6 expression in 509 cases of various epithelial tumors by immunohistochemistry. We found that the vast majority of cases of squamous cell carcinoma, basal cell carcinoma, thymoma, salivary gland tumor, and biphasic malignant mesothelioma were positive for CK 5/6. In addition, CK 5/6 immunoreactivity was detected in 15 of 24 cases (62%) of transitional cell carcinoma, in 5 of 10 cases (50%) of endometrial adenocarcinoma, in about one third of cases of pancreatic adenocarcinoma (38%) and breast adenocarcinoma (31%), and in one quarter of cases of ovarian adenocarcinomas (25%). Our study confirms the diagnostic utility of CK 5/6 immunohistochemistry in distinguishing biphasic mesothelioma from pulmonary adenocarcinoma but raises caution about its use for the differential diagnosis of pleural or peritoneal malignant mesothelioma versus pleural or peritoneal metastatic nonpulmonary adenocarcinoma, because many types of nonpulmonary adenocarcinomas may be positive for CK 5/6.